"METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH LPA-TARGETED RNAi CONSTRUCTS" in Patent Application Approval Process (USPTO 20230405040).

Amgen Inc. has filed a patent application outlining methods for treating atherosclerotic cardiovascular disease by targeting Lp(a) levels using RNAi constructs. Elevated Lp(a) levels have been linked to a higher risk of coronary artery disease and other cardiovascular disorders. The application proposes using an LPA RNAi construct called olpasiran to effectively lower Lp(a) concentrations. The methods involve administering the construct at specific doses and intervals to reduce serum or plasma Lp(a) levels and treat or prevent atherosclerosis and cardiovascular disease. These methods may be particularly beneficial for patients with elevated Lp(a) levels who are at risk of developing cardiovascular events. [Extracted from the article]